Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia.

OBJECTIVE To evaluate the clinical usefulness of sulbactam/ampicillin therapy for community-acquired pneumonia in the elderly. METHODOLOGY A randomized prospective clinical study was conducted in the elderly patients with moderate-to-severe community-acquired bacterial pneumonia. RESULTS Overall clinical efficacy of sulbactam/ampicillin therapy (6 g/day) in these patients (efficacy rate: 91.4%) was comparable to that of imipenem/cilastatin therapy (1 g/day; efficacy rate: 87.5%), when each therapy was administered intravenously twice daily for 7-14 days. With regard to clinical efficacy based on disease severity, bacteriological efficacy, improvement of chest X-ray findings and adverse reactions, the two therapies were comparable. CONCLUSION These results suggest that sulbactam/ampicillin therapy has excellent efficacy and tolerability and that it may be highly effective, even in severe cases of pneumonia. This regimen may thus serve as first-line treatment for the treatment of community-acquired pneumonia in elderly patients.

[1]  笠原 敬,et al.  The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults , 2008 .

[2]  M. Kaufmann,et al.  Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-8, a Novel Metallo-β-Lactamase, in a Tertiary Care Center in Cali, Colombia , 2004, Journal of Clinical Microbiology.

[3]  T. Matsushima.  [The Japanese Respiratory Society guidelines for management of community-acquired pneumonia in adults]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[4]  T. Fabian,et al.  Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  T. File,et al.  Etiology and management of community-acquired pneumonia in Asia , 2002, Current opinion in infectious diseases.

[6]  M. Gniadkowski.  Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  H. Arai,et al.  Interventions to Prevent Pneumonia Among Older Adults , 2001, Journal of the American Geriatrics Society.

[8]  T. Ishida,et al.  Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. , 1998, Chest.

[9]  Yasuaki Yamada,et al.  Rapid Detection and Evaluation of Clinical Characteristics of Emerging Multiple-Drug-Resistant Gram-Negative Rods Carrying the Metallo-β-Lactamase GeneblaIMP , 1998, Antimicrobial Agents and Chemotherapy.

[10]  M. Fine,et al.  Influence of age on symptoms at presentation in patients with community-acquired pneumonia. , 1997, Archives of internal medicine.

[11]  A. Fietta,et al.  New Developments in Antibacterial Choice for Lower Respiratory Tract Infections in Elderly Patients , 2004, Drugs & aging.

[12]  N. Asaoka,et al.  Clinical effect of ampicillin with β-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly , 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[13]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.

[14]  Inger,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[15]  S. Teramoto.  Etiology of Community-Acquired Pneumonia Requiring Hospitalization in Japan , 2022 .